Environmental impact and costs of a switching program of intravenous to subcutaneous infliximab in Inflammatory Bowel Disease

Utilize este identificador para referenciar este registo.

Nome:	Descrição:	Tamanho:	Formato:
Environmental impact and costs of a switching program of intravenous to subcutaneous infliximab in Inflammatory Bowel Disease.pdf		476.23 KB	Adobe PDF	Ver/Abrir

Autores

We aimed to compare real-life direct and indirect costs and the environmental impact of switching IBD patients from IV to SC infliximab (IFX).

Oxford University Press